Last update 11 Jul 2024

Vebreltinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Bozitinib
+ [3]
Target
Mechanism
c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)
Originator Organization
Drug Highest PhaseApproved
RegulationConditional marketing approval (CN), Special Review Project (CN), Orphan Drug (US), Priority Review (CN), Breakthrough Therapy (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC20H15F3N8
InChIKeyQHXLXUIZUCJRKV-UHFFFAOYSA-N
CAS Registry1440964-89-5

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Astrocytoma, IDH-Mutant
CN
17 Apr 2024
Glioblastoma
CN
17 Apr 2024
MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer
CN
14 Nov 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
RU
27 Sep 2017
Advanced Malignant Solid NeoplasmPhase 2
FI
27 Sep 2017
Advanced Malignant Solid NeoplasmPhase 2
TW
27 Sep 2017
Advanced Malignant Solid NeoplasmPhase 2
ES
27 Sep 2017
Advanced Malignant Solid NeoplasmPhase 2
US
27 Sep 2017
Advanced Malignant Solid NeoplasmPhase 2
AU
27 Sep 2017
Advanced Malignant Solid NeoplasmPhase 2
SG
27 Sep 2017
Advanced Malignant Solid NeoplasmPhase 2
PR
27 Sep 2017
Advanced Malignant Solid NeoplasmPhase 2
FR
27 Sep 2017
Advanced Malignant Solid NeoplasmPhase 2
GB
27 Sep 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
52
(txfranfvns) = iemfwsryqq nphaljkvqm (fsuxcrvixx, 61.1 - 86.0)
Positive
24 May 2024
Phase 2/3
Glioblastoma
PTPRZ1-MET Fusion gene positive
84
(qqiopjulan) = orfhvsrvwm porpuyjfka (ijxnhgsbtw, 4.44 - 8.77)
Positive
24 May 2024
Chemotherapy (temozolomide or cis-platinum combined with etoposide)
(qqiopjulan) = qvxesyqrhb porpuyjfka (ijxnhgsbtw, 2.37 - 4.27)
Phase 2
MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer
Second line
MET exon 14 skipping mutation
1
Tepotinib
(ahhvllfebq) = uoaolkllee wmpfrqufhy (fvriftkyui )
Positive
01 Jan 2024
(ahhvllfebq) = xixlbimmmt wmpfrqufhy (fvriftkyui )
Phase 2
500
(gene copy number<4)
(dyjrdkjrkp) = umzsfebmij ufxjtppxlb (wktsjudlyp )
Positive
04 Dec 2023
(GCN≥4)
(dyjrdkjrkp) = skmratqcid ufxjtppxlb (wktsjudlyp )
Phase 2
52
(pgmpalptyd) = kivxmgsljc qhlxxiuuwx (lvcvzrmgac, 61.1 ~ 86.0)
Positive
23 Oct 2023
(treatment-naïve pts)
(pgmpalptyd) = cdhscysqon qhlxxiuuwx (lvcvzrmgac, 59.9~89.6)
Phase 1
37
(sbbpqszkhi) = cqelobdafx syuxpoomae (blubbsdffa )
Positive
15 Aug 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free